Logo for ImmunoGen Inc

ImmunoGen Investor Relations Material

Latest events

Logo for ImmunoGen Inc

Q3 2023

ImmunoGen
Logo for ImmunoGen

Q3 2023

2 Nov, 2023
Logo for ImmunoGen

Corporate Presentation

1 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from ImmunoGen Inc

Access all reports
ImmunoGen, Inc., is a clinical-stage biotechnology company. The company develops antibody-drug conjugate therapies to treat cancer. Its ADC product candidates include Binimetinib, an ADC designed to treat non-small cell lung cancer, colorectal cancer, and pancreatic cancer; Daratumumab, an ADC designed to treat multiple myeloma; and SAR302503, an ADC that combines trastuzumab with an anthracycline. The company's ADC product candidates are currently in various stages of clinical development. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.